SABCS: Interrupting Endocrine Therapy Does Not Pose Breast Cancer Recurrence Risk

WEDNESDAY, Dec. 14, 2022 -- For young women with early-stage hormone receptor (HR)-positive breast cancer (BC) desiring pregnancy, temporary interruption of endocrine therapy does not confer a greater short-term risk for recurrence than not...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news